How Retatrutide Affects Triglycerides

Triglycerides circulate primarily as VLDL particles secreted by the liver, with smaller contributions from intestinal chylomicrons. Retatrutide reduces triglycerides through complementary mechanisms:

1. Reduced hepatic VLDL secretion: GLP-1 receptor activation in the liver reduces de novo lipogenesis and VLDL output. This is the same mechanism behind semaglutide's modest triglyceride reduction, but retatrutide's effect is stronger.
2. Glucagon arm enhances fatty acid oxidation: Glucagon receptor activation increases hepatic and peripheral fatty acid oxidation, reducing the substrate pool available for triglyceride synthesis. This is unique to retatrutide among the obesity drugs and accounts for much of the additional triglyceride lowering versus semaglutide and tirzepatide.
3. Massive hepatic fat clearance: The Phase 2a MASLD trial (Sanyal 2024) showed about 82 percent relative liver fat reduction at 8mg and 12mg, with 90 percent achieving complete steatosis resolution. A fatty-free liver produces dramatically less VLDL.
4. Weight loss and insulin sensitisation: 20 to 28 percent body weight loss (TRIUMPH-1) reduces the insulin resistance that drives hepatic lipogenesis and impaired VLDL clearance.
5. Reduced dietary fat absorption: Delayed gastric emptying may modestly reduce post-prandial chylomicron output.

The result in Phase 2 (Jastreboff 2023): triglycerides dropped up to 40.6 percent at 12mg over 48 weeks, with parallel reductions of non-HDL-C up to 26.9 percent and ApoB up to 24.2 percent. These are the largest lipid improvements documented for any incretin-class drug.

Lower doses (1mg to 4mg weekly):

• Triglyceride reduction of 15 to 25 percent over 24 to 48 weeks
• Non-HDL-C drops 10 to 15 percent
• ApoB drops 8 to 12 percent

Higher doses (8mg to 12mg weekly):

• Triglyceride reduction of 30 to 40 percent at 12mg (Phase 2)
• Non-HDL-C drops up to 26.9 percent
• ApoB drops up to 24.2 percent
• HDL-C modest rise (5 to 10 percent), atypical for caloric restriction alone

In bodybuilders with elevated baseline triglycerides:

• AAS users with low HDL and high triglycerides from oral steroid cycles often see the largest absolute reductions
• A user with baseline triglycerides of 250 mg/dL may see drops to 130 to 150 mg/dL within 16 to 24 weeks
• The lipid improvement does not fully offset the HDL crash from orals but does meaningfully reduce overall atherogenic burden

Timeline: Triglyceride drop begins within 4 to 8 weeks. Maximum effect at 24 to 48 weeks as weight loss and hepatic fat clearance accumulate.

Baseline: Full lipid panel including triglycerides, total cholesterol, HDL, LDL (calculated and direct if possible), non-HDL-C, and ApoB before starting.

Early phase (first 24 weeks): Lipid panel at week 12 and week 24 to track trajectory. ApoB is the load-bearing marker during active weight loss because the LDL-C calculation becomes less reliable when triglycerides shift rapidly.

Stable phase: Lipid panel every 24 weeks once weight has stabilised.

Triglyceride above 500 mg/dL at baseline: Severe hypertriglyceridaemia is a pancreatitis risk independent of GLP-1 effects. Treat aggressively before or in parallel with starting retatrutide.

Triglyceride drops dramatically but LDL rises during active fat mobilisation: This is a known artefact of weight loss. If ApoB is dropping, the LDL rise is not pathological. Audit dietary saturated fat if ApoB is also rising.

Fasting required: Triglyceride accuracy depends on a 12-hour fast. Non-fasting samples overestimate triglycerides by 20 to 60 mg/dL.

Maximising the triglyceride benefit:

• Pair retatrutide with a low-refined-carbohydrate diet to amplify hepatic fat clearance
• Reduce alcohol consumption (alcohol is a potent driver of hepatic VLDL secretion)
• Aerobic training augments triglyceride clearance via lipoprotein lipase upregulation

For AAS users with low HDL from orals:

• Retatrutide does not reverse the HDL crash from oral steroids (which works through hepatic lipase upregulation, a different mechanism)
• It does reduce the atherogenic non-HDL-C and ApoB burden, partially offsetting cardiovascular risk
• Combining retatrutide with a clean oral cycle structure (shorter duration, lower dose, cycle support) gives the best overall lipid profile

If using GH alongside retatrutide:

• GH lowers triglycerides modestly through stimulating lipolysis and fat oxidation
• The combination is additive: TG reductions of 40 to 50 percent are achievable
• Useful for athletes with persistently high TG who do not respond to diet alone

For users with very high baseline triglycerides (above 500 mg/dL):

• Start fenofibrate or omega-3 (icosapent ethyl or high-EPA fish oil) before starting retatrutide
• Pancreatitis risk is already elevated at these triglyceride levels; do not rely on retatrutide alone for the acute reduction

Discontinuation: Triglycerides drift back toward baseline over 8 to 16 weeks after stopping unless weight loss and dietary changes are sustained.